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Abstract
Type 2 innate lymphoid cells (ILC2s) both contribute to mucosal homeostasis and initiate 
pathologic inflammation in allergic asthma. However, the signals that direct ILC2s to promote 
homeostasis versus inflammation are unclear. To identify such molecular cues, we profiled mouse 
lung-resident ILCs using single-cell RNA sequencing at steady state and after in vivo stimulation 
with the alarmin cytokines IL-25 and IL-33. ILC2s were transcriptionally heterogeneous after 
activation, with subpopulations distinguished by expression of proliferative, homeostatic and 
effector genes. The neuropeptide receptor Nmur1 was preferentially expressed by ILC2s at steady 
state and after IL-25 stimulation. Neuromedin U (NMU), the ligand of NMUR1, activated ILC2s 
in vitro, and in vivo co-administration of NMU with IL-25 strongly amplified allergic 
inflammation. Loss of NMU–NMUR1 signalling reduced ILC2 frequency and effector function, 
and altered transcriptional programs following allergen challenge in vivo. Thus, NMUR1 
signalling promotes inflammatory ILC2 responses, highlighting the importance of neuro-immune 
crosstalk in allergic inflammation at mucosal surfaces.
Given the increased prevalence of allergy and asthma, identifying the molecular pathways 
that modulate the response of type 2 innate lymphoid cells (ILC2s) to alarmins is an 
important area of inquiry. Damaged or stressed epithelial cells produce alarmin cytokines, 
such as IL-25 and IL-33, which activate ILC2s1–5. Activated ILC2s initiate allergic tissue 
inflammation at mucosal surfaces, in part by rapidly producing effector cytokines, such as 
IL-5 and IL-136–8. ILC2s also maintain tissue homeostasis by promoting epithelial cell 
proliferation, survival, and barrier integrity9. However, the factors that balance homeostatic 
and inflammatory ILC2 responses are unknown, as is whether distinct ILC2 subsets mediate 
these effects.
It is challenging to distinguish homeostatic from pro-inflammatory ILC2s, since there are 
few known markers of these functional states. Single-cell genomics, especially single-cell 
RNA-sequencing (scRNA-seq)10,11, can identify such diversity, both when changes in cell 
states are continuous across a population12 and when there are discrete subpopulations of 
varying sizes, including in intestinal ILCs13–15.
Alarmins induce heterogeneity in ILC2s
To define the transcriptional landscape of lung-resident ILCs, we collected 24,187 high-
quality, droplet-based scRNA-seq profiles of ILCs (IL-7Ra+CD90+ and lacking lineage 
markers) at steady state and after in vivo activation by IL-25 or IL-33 (Fig. 1a, Extended 
Data Fig. 1a–c). We scored cells based on expression of ILC subset-specific signature genes 
(after condition-specific normalization, Methods), and classified cells as ILC1, ILC2, ILC3, 
‘mixed’, or ‘none’ if no score was sufficiently high (Extended Data Fig. 1d–f, Methods). 
Mixed profile ILCs could either represent a transient or plastic transcriptional state or cell 
doublets. Expression of key signature genes (for example, Tbx21, Il1rl1, Rorc) supported 
our cell classification (Extended Data Fig. 1g). ILC2s composed greater than 94% of cells in 
all conditions; IL-33 increased their proportion further, whereas IL-25 increased the 
proportion of ILC3s (Extended Data Fig. 1e) (multinomial logistic; IL-33, P < 2.2 × 10−16; 
IL-25, P < 8.4 × 10−8).
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Alarmin treatment induced unique gene expression programs, as suggested by the 
relationship between the expression profiles of cells from different treatment conditions, 
independent of experimental batch (Fig. 1a, Extended Data Fig. 1h). IL-25 and IL-33 both 
upregulated genes associated with ILC2 activation, including Il5, Klrg1, and Arg1, while 
other genes, such as Areg, were preferentially induced by one alarmin but not the other 
(Extended Data Fig. 1i)2,16.
We partitioned transcriptionally distinct ILCs into 11 clusters (Fig. 1b). All clusters 
exhibited high expression of key marker genes of ILCs, while markers of other cell types 
were minimally expressed, except for CD3 genes (Extended Data Fig. 1j; Cd3d), which have 
previously been observed at the mRNA level in ILCs17,18. ILC1s, ILC2s and ILC3s largely 
partitioned into distinct clusters. ILC1s composed approximately 50% of cluster 1 (392 
cells; 56% of ILC1s), ILC3s and mixed ILCs each made up around 25% of cluster 2 (926 
cells; 64% of ILC3s), and the remaining clusters (22,869 cells) were predominantly 
composed of ILC2s, particularly clusters 3–5 and 8–11 (Fig. 1c, Extended Data Fig. 1k). 
Cluster assignment is strongly associated with treatment (χ2 test, P < 2.2 × 10−16): most 
cells in clusters 7 and 9–11 are IL-33-activated ILCs, while cells in clusters 5 and 8 are 
primarily IL-25-activated ILCs, and control ILC2s comprise approximately 90% of clusters 
3 and 4 (Fig. 1d, Extended Data Fig. 1l).
Alarmin-activated ILCs express 1.5–2.5-fold more genes than do resting ILCs, partly owing 
to proliferation, particularly among IL-33-activated ILC2s (Extended Data Fig. 1c). Clusters 
7 and 11, enriched with such cells, scored highly for a proliferative gene signature (t-test, P 
< 2.2 × 10−16) (Fig. 1e)19,20. Consistent with this, IL-33 induced more robust proliferation 
of ILCs in vitro than did IL-25 (Extended Data Fig. 2).
To uncover novel molecular cues that regulate ILC responses, we identified genes that were 
differentially expressed across clusters by fitting gene counts to mixtures of generalized 
linear models that account for variation in both dropout rates and proliferation (Methods, 
Supplementary Table 1). Highly differentially expressed genes include both those with 
known and novel roles in ILC biology (Fig. 1f). Among known genes, Arg1, Il13 and Klrg1 
are highly expressed in clusters where alarmin-activated ILC2s are predominant. Other 
genes discriminate between cells activated by a single alarmin. For example, clusters 5 and 8 
both consist predominantly of IL-25-activated ILC2s, yet Ms4a4b is expressed only in 
cluster 8. Similarly, Ctla4 was induced only in certain clusters of IL-25- or IL-33-activated 
cells (Fig. 1f).
We validated the expression patterns at the protein level for a number of genes using flow 
cytometry (Extended Data Fig. 1m). As predicted, KLRG1, gp49 (Lilrb4a), and Batf were 
upregulated after activation by IL-25 and IL-33. Expression of semaphorin 4a (Sema4a) was 
reduced in IL-33-activated ILCs, mirroring the lower expression in IL-33-dominant scRNA-
seq clusters. Finally, consistent with the scRNA-seq data, only a subset of ILCs upregulated 
CTLA4 or MHC class II after alarmin activation. These results suggest that distinct 
functional states exist within defined ILC subsets, and that IL-33 and IL-25 differentially 
regulate these states.
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Studies in other systems have shown that analysis of large cell numbers, even at shallow 
coverage, can readily identify markers of transcriptional states14,21. However, the number of 
distinct transcripts per cell in droplet-based scRNA-seq may be lower than in full-length 
protocols22,23. To explore the possible impact of these differences, we complemented our 
droplet-based survey with an analysis using a plate-based full-length protocol23.
We analysed 606 high-quality full-length scRNA-seq profiles of ILCs from phosphate-
buffered saline (PBS)-, IL-25-, or IL-33-treated mice (Fig. 2a, Extended Data Fig. 3a). Most 
cells were classified as ILC2s, consistent with our droplet-based atlas (Extended Data Fig. 
3b–e). The two datasets were highly concordant in terms of the similarity of expression 
profiles (Extended Data Fig. 4a), clustering (Fig. 1a, b versus Fig. 2a, b), and top genes 
identified by principle component analysis (PCA) or differential expression analysis (for 
example, Lpcat2, Anxa2, Lgals3bp, Ms4a4b) (Fisher’s exact test, P < 3.74 × 10−80, for PCA 
genes) (Figs 1f, 2c).
Of the differentially expressed genes in plate-based scRNA-seq, Nmur1 (also known as 
Gpr66 and FM-3) was highly expressed in ILC2s at steady state and after IL-25 stimulation, 
but was downregulated by IL-33 (Fig. 2c), and yet was essentially absent in the initial 
droplet-based scRNA-seq analysis (Extended Data Fig. 4a). Alignment of bulk, full-length 
RNA-seq indicated that the Nmur1 transcript extends to a different 3′ end in lung ILCs than 
is annotated in the reference transcriptome (Extended Data Fig. 4b). Upon correcting the 
Nmur1 annotation, Nmur1 was recovered in the droplet-based data (Extended Data Fig. 4c). 
By contrast, Rapgef4, another of the few differentially expressed genes absent in the droplet-
based data, has an annotated 3′ end consistent with the bulk RNA-seq, indicating that 
technical issues other than transcriptome annotation also contribute to discrepancies 
(Extended Data Fig. 4d). Overall, however, both droplet and plate data supported the same 
global trends, including the differential expression of Nmur1.
ILC2-specific expression of NMUR1
NMUR1 is a receptor for the neuropeptide NMU, and NMU–NMUR1 signalling modulates 
inflammatory responses24, although the role of this pathway in ILCs was unknown. We 
found that Nmur1 expression was largely specific to ILCs, compared to other lung-resident 
cell populations. It was highly expressed in ST2+ ILCs both at steady state and after 
induction of airway inflammation with house dust mite (HDM) extract (Fig. 2d). In either 
setting, the only non-ILC population with detectable Nmur1 expression was CD4+ T cells, 
which expressed very low levels both after HDM-challenge in vivo, as well as after T helper 
2 (TH2) differentiation in vitro (Fig. 2d, Extended Data Fig. 5a). Nmur2, the other known 
receptor for NMU, was not detectably expressed in lung-resident cells, including ILCs, but 
was expressed in the central nervous system, as previously reported (Extended Data Fig. 
5b)25–27.
We assessed NMUR1 protein expression by flow cytometry of cells from heterozygous 
Nmur1-LacZ reporter mice. Approximately 40% of ST2+ ILCs expressed NMUR1 (Fig. 2e, 
Extended Data Fig. 5c). Only ILC2s had notable specific staining, although several myeloid 
cell types demonstrated non-specific staining independent of the reporter allele (Extended 
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Data Fig. 5d). Treatment in vivo with IL-25 did not alter the frequency of NMUR1+ ILCs, 
whereas IL-33 markedly reduced their frequency (Fig. 2f). Regardless of alarmin treatment, 
NMUR1 was predominantly expressed by ST2+ ILCs and did not correlate with expression 
of IL-17RB, the receptor for IL-25 (Extended Data Fig. 5e).
ILCs express several neuropeptide receptors in addition to NMUR128,29, raising the 
possibility that neurons communicate directly to ILCs. Immunofluorescence microscopy 
showed that around 70% of CD3−KLRG1+ cells are within 10 μm of SNAP-25+ nerve fibres 
(Extended Data Fig. 6a). The nodose/jugular ganglion and thoracic dorsal root ganglia 
(DRG) both contain sensory afferent neurons innervating the lung28,30, and neurons in the 
DRG, although not in the nodose/jugular ganglion, express Nmu (Extended Data Fig. 6b). 
Additionally, IL-13 induced upregulation of Nmu in cultured DRG neurons, suggesting ILCs 
may also communicate with neurons (Extended Data Fig. 6c).
NMU amplifies IL-25-driven inflammation
We next investigated whether NMU affected ILC production of type 2 cytokines in vitro. 
While NMU did not affect cytokine expression by TH2 cells (Extended Data Fig. 7a) and 
only mildly upregulated Il5 and Il13 in cultured ILC2s, NMU markedly increased their 
mRNA and protein expression when combined with IL-25, suggesting that NMU modulates 
ILC2 responses to alarmins (Fig. 3a, b, Extended Data Fig. 7b). The combination of IL-33 
and NMU also increased IL-5 and IL-13 expression, but to a lesser extent than IL-25 
combined with NMU (Extended Data Fig. 7c).
The synergy between IL-25 and NMU was even more notable in vivo. NMU alone did not 
increase expression of Il5 or Il13 mRNA in lung tissue, and only trace quantities of IL-5 
protein were detectable in the bronchoalveolar lavage fluid (BALF), consistent with a small 
increase in BALF eosinophils (Extended Data Fig. 7d–h). IL-25 modestly induced 
expression of IL-5 and IL-13 in the lung and BALF, while the combination of IL-25 and 
NMU strongly increased their expression (Fig. 3c, Extended Data Fig. 7i). Moreover, IL-25 
combined with NMU increased lung and BALF eosinophilia, and markedly enhanced 
histopathologic evidence of inflammation (Fig. 3d, e, Extended Data Fig. 7j). Finally, IL-25 
combined with NMU induced significant airway hyper-reactivity (Fig. 3f). In summary, 
NMU converted a non-pathologic dose of IL-25 into a pathologic one.
To understand the role of endogenous NMU in ILC function, we analysed ILCs in NMU-
deficient (Nmu-knockout) mice. At steady state, both the overall frequency of ILCs and ILC 
expression of KLRG1, ST2, IL-5, and IL-13 were unchanged in Nmu-knockout versus wild-
type mice (Extended Data Fig. 8a–c). After challenge with HDM, total cell numbers and 
eosinophil frequencies in BALF were similar in wild-type and Nmu-knockout mice 
(Extended Data Fig. 8d). However, the frequency of ST2+ ILCs after HDM challenge was 
reduced in Nmu-knockout mice, compared to wild-type mice (Fig. 3g), and a lower 
percentage of ILCs expressed IL-5 and IL-13 ex vivo (Fig. 3h). The frequency of lung-
infiltrating CD4 T cells was higher in Nmu-knockout mice, while the frequency of T cells 
expressing type 2 cytokines ex vivo was unchanged, suggesting potential adaptive immune 
compensation that could explain the similar degree of BALF eosinophilia (Extended Data 
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Fig. 8e, f). Overall, the reduced frequency of ILC2s expressing effector cytokines after 
allergen challenge in Nmu-knockout mice indicates that NMU promotes ILC activation and 
effector function.
IL-25 combined with NMU expands inflammatory ILC2s
To characterize how IL-25 and NMU synergistically promote allergic inflammation, we 
profiled lung-resident ILCs by scRNA-seq after in vivo treatment with NMU alone or in 
combination with IL-25 (Fig. 4a, Extended Data Fig. 9a, b). NMU-treated ILCs were 
transcriptionally similar to control ILCs, consistent with the minimal in vivo impact of NMU 
alone (Fig. 4a), whereas the expression profiles of ILCs treated with a combination of IL-25 
and NMU were distinct from those of IL-25- and NMU-treated ILCs, and comparable to 
those of IL-33-activated ILCs (Extended Data Fig. 9c). We analysed profiles from ILCs 
treated with PBS, NMU, IL-25 and IL-25 combined with NMU, partitioning them into 11 
clusters (Fig. 4b). There was a significant association between cluster and treatment (χ2 test, 
P < 2.2 × 10−16). Five clusters (6 and 8–11) consisted almost exclusively of cells activated 
by IL-25 or IL-25 combined with NMU (Extended Data Fig. 9d, e), suggesting that IL-25 
combined with NMU expands transcriptionally distinct subsets of ILCs present at lower 
numbers in IL-25-treated mice.
One mechanism by which IL-25 and NMU synergized was by inducing proliferation in 
distinct subpopulations of ILCs. Mice treated with IL-25 combined with NMU had increased 
ILC frequencies and approximately twice as many Ki67+ ILCs as IL-25-treated mice, 
indicating significant proliferation (Fig. 4c, Extended Data Fig. 9f). Cells activated by IL-25 
combined with NMU had bimodally distributed proliferative signature scores (Fig. 4d), as 
cells in IL-25 and NMU-dominated cluster 11 scoring higher than cells in other clusters (t-
test, P < 2.2 × 10−16, Extended Data Fig. 9g).
Another mechanism by which NMU could amplify IL-25-initiated ILC responses is by 
upregulating IL-17RB on ILCs. Compared to IL-25 alone, IL-25 combined with NMU 
increased the frequency of IL-17RB+ ILCs by flow cytometry and upregulated the 
expression of Il17rb mRNA in the lung by quantitative real-time PCR (qPCR) (Fig. 4e, 
Extended Data Fig. 9h). The frequency of Il17rb-expressing ILCs was also increased in the 
scRNA-seq profiles from mice treated with IL-25 combined with NMU (Fig. 4f, logistic 
regression, P < 2.73 × 10−10). Finally, IL-17RB+ ILC frequency after HDM challenge was 
reduced in Nmu-knockout versus wild-type mice (Fig. 4g), suggesting that NMU potentiates 
ILC responsiveness to IL-25 following both allergen challenge and alarmin stimulation.
We analysed differential gene expression between IL-25 combined with NMU and other 
conditions, focusing on genes with a non-additive pattern of expression. One subset of such 
genes, including Il1r2, Tnfrsf8 (CD30) and Mt1, was strongly upregulated specifically by 
IL-25 combined with NMU (Fig. 4h). A second subset, including Zfp36l1 and Csf2, was 
downregulated by IL-25 combined with NMU, even though it was upregulated after 
treatment with IL-25 and/or NMU alone. Finally, a few genes (for example, Btg2 and Fosb) 
were expressed at steady state and in single-treatment conditions at similar levels, but were 
downregulated by IL-25 combined with NMU. We validated these expression patterns for 
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several representative genes by flow cytometry. Consistent with the scRNA-seq data, both 
CD30 and IL-1R2 were upregulated only by IL-25 combined with NMU; galectin-3 (Lgals3) 
and gp49 (Lilrb4a) were upregulated by either NMU or IL-25 alone and further induced by 
IL-25 combined with NMU; and NR4A1 expression was highest in response to IL-25 alone 
(Extended Data Fig. 9i).
Several of these genes have previously been linked to allergic airway inflammation in both 
mice and humans. Mice lacking Tnfrsf8 and Anxa2 have reduced airway inflammation in 
asthma models31,32. Tnfrsf8, Anxa2 and Il1r2 are overexpressed in allergic asthmatics33–35. 
Deletion of Nr4a1, which is downregulated by IL-25 combined with NMU, exacerbates 
airway inflammation in mice, suggesting a potential role in limiting inflammatory ILC 
responses36.
Cluster-based analysis of differentially expressed genes further highlighted that ILCs from 
mice treated with IL-25 combined with NMU were transcriptionally heterogeneous (Fig. 4b, 
Extended Data Fig. 9j). Some genes, such as Il13, were highly expressed in all clusters 
principally composed of ILC2s treated with IL-25 combined with NMU or IL-25 (clusters 
6–11), while other genes were specific to certain clusters. For example, Ifitm3 was highly 
expressed in ILCs in cluster 10, whereas ILCs in cluster 7, which were also expanded by 
IL-25 combined with NMU, co-expressed key antigen-presentation genes, including MHC 
class II (for example, H2-Ab1) and the invariant chain (Cd74). IL-25 combined with NMU 
also increased the frequency of a population of MHC-IIhi ILCs as determined by flow 
cytometry (Extended Data Fig. 9i). Cluster 8 primarily consisted of ILCs treated with IL-25 
or IL-25 combined with NMU that expressed Klrg1, Il13 and Il4, as well as some Il17a, but 
little Il1rl1 and Il5, similar to previous reports of an IL-25-induced KLRG1hiST2− 
inflammatory ILC2 (iILC2) population2. ILCs of cluster 8 also expressed Nmur1, as did 
cells in IL-25 predominant cluster 6, suggesting that these two subsets are preferentially 
NMU-responsive. Flow cytometry revealed that NMUR1 was expressed by IL-25-treated 
ILCs, including iILC2s (Extended Data Fig. 9k). While both IL-25 combined with NMU 
and IL-33 downregulated NMUR1 on ILC2s, IL-25 combined with NMU uniquely 
expanded the population of iILC2s, suggesting that NMU–NMUR1 signalling preferentially 
modulates the activation and/or expansion of certain IL-25-induced iILC2 subsets (Extended 
Data Fig. 9l, m).
NMUR1 promotes ILC2 activation by HDM
To further characterize the impact of NMUR1 signalling on ILCs, we challenged wild-type 
and Nmur1-knockout mice with HDM and profiled lung-resident ILCs by scRNA-seq. 
Analysis of 21,895 high-quality profiles largely clustered them by in vivo treatment, 
regardless of genotype or batch (Fig. 5a, Extended Data Fig. 10a, b). In Nmur1-knockout 
mice, ILC2 frequency was markedly reduced after HDM challenge compared to PBS (76% 
versus 91%; multinomial logistic, P < 2.2 × 10−16), exaggerating a trend also seen in wild-
type mice (87% versus 94%, multinomial logistic, P < 2.2 × 10−16), which is consistent with 
the reduced frequency of ST2+ ILCs in Nmu-knockout mice after HDM challenge (Fig. 5b, 
Extended Data Fig. 10c, d). While IL-25 combined with NMU and IL-33 induced robust 
proliferation and increased ILC2 frequency, HDM challenge only induced a high 
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proliferation score in the cells of one small cluster (cluster 6, 210 cells) (Fig. 1e, Extended 
Data Figs 1e, 10e–h). This minimal induction of proliferation, in conjunction with an 
increase in ILC1s and ILC3s, may be related to the observed reduction in ILC2 frequency 
after HDM challenge.
Based on genes differentially expressed between HDM- and PBS-treated wild-type ILC2s, 
we defined an inflammatory ILC2 signature (Fig. 5c–e). ILCs from mice treated with IL-25 
combined with NMU scored highly for this inflammatory signature, suggesting that it 
identifies inflammatory ILC2s independent of the model of airway inflammation (Fig. 5d, 
e). Differentially expressed genes in ILC2s from HDM-treated mice significantly overlapped 
with those in ILCs from mice treated with IL-25 combined with NMU (Fisher’s exact test, P 
< 1.64 × 10−25). Finally, Nmur1-knockout ILC2s had a lower average inflammatory score 
than wild-type ILC2s after HDM challenge (t-test, P < 4.9 × 10−15), consistent with NMU–
NMUR1 signalling promoting ILC2 responses in vivo (Fig. 5e).
Discussion
We used massively parallel droplet-based scRNA-seq to establish the transcriptional 
landscape of lung-resident ILCs under homeostatic and inflammatory conditions, and 
identified NMUR1 as a modulator of alarmin- and allergen-driven ILC2 responses. Nmu-
knockout mice were previously reported to develop attenuated airway inflammation after 
allergic sensitization24, but the underlying mechanism was unclear. NMU expression in 
bronchial brushing samples from asthmatic patients correlates with disease severity, which 
our data suggests could be related to the effect of NMU on ILC function37. Functional 
analysis and scRNA-seq-based approaches both demonstrate that, in the absence of NMU–
NMUR1 signalling, ILC2s are decreased in frequency and have impaired effector function 
after allergen challenge. Although the inflammatory signature score of allergen-challenged 
NMUR1-deficient ILC2s is significantly decreased compared to allergen-challenged wild-
type ILC2s, it is still increased compared to PBS-treated controls, suggesting that other 
factors, in addition to NMU, contribute to ILC activation in this context.
Our findings raise the question of whether NMU potentiates airway inflammation when high 
levels of alarmins, such as IL-25, are present, as is the case in steroid-naive TH2-high asthma 
or post-viral asthma exacerbations1,38. While airway epithelial cells upregulate IL-25 in 
response to stress, chemosensory cells, which are found in both the intestine and trachea, 
constitutively produce IL-25 and modulate mucosal immune responses39–43. Our 
observation that NMU is expressed by neurons from thoracic DRG suggests that the 
coordinated action of neurons and chemosensory cells could promote tissue-based, ILC-
dependent type 2 immune responses. Given the importance of smooth muscle contraction in 
the clinical manifestations of allergic diseases, it is intriguing that NMU can induce both 
smooth muscle contraction44 and ILC2-driven inflammation. Neuronal activation following 
inhalation of noxious substances or allergens could potentially trigger both processes, 
simultaneously promoting physical expulsion and allergic immunity to the provoking 
stimulus. Taken together, our findings demonstrate a novel neuro-immune pathway that 
exacerbates mucosal allergic inflammation in vivo.
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METHODS
Mice and in vivo ILC activation
C57Bl/6J mice were purchased from the Jackson Laboratory. Nmur1-LacZ reporter mice 
with a LacZ cassette knocked into the Nmur1 locus were rederived from 
Nmur1tm1.1(KOMP)Vlcg sperm obtained from the trans-NIH Knockout Mouse Project 
(KOMP) Repository. NMU-deficient mice (Nmu-knockout) were rederived from B6.129S2-
NMU < tm1Mko > embryos from the RIKEN BioResource Center. For experiments with 
Nmur1-LacZ (Nmur1-knockout) and Nmu-knockout mice, littermates that were either 
homozygous or heterozygous for the wild-type allele were used as controls. Mice were 
housed under specific-pathogen-free conditions. For experiments, mice were matched for 
sex and age, and most mice were 6–10 weeks old. Where indicated, mice were anaesthetized 
with isoflurane and treated intranasally with the indicated stimuli (500 ng IL-25, 500 ng 
IL-33, or 20 μg neuromedin U) daily for three consecutive days. The total administered 
volume was 20 μl for all conditions. Mice were randomly assigned to treatment groups after 
matching for sex and age. Airway inflammation was also induced with house dust mite 
(HDM) extract (Greer Laboratories). Mice were treated intranasally with 10 μg HDM on day 
0, 7, 8 and 9, before being euthanized on day 10. No power analysis was performed. The 
investigators were not blinded to allocation during experiments and outcome assessment 
except for the severity score of airway inflammation. All experiments were conducted in 
accordance with animal protocols approved by the Harvard Medical Area Standing 
Committee on Animals or BWH IACUC.
Flow cytometry
For flow cytometric analysis CD3ε (clone: 145-2C11), CD4 (clone: RM4-5), CD8a (clone: 
53-6.7), CD11b (clone: M1/70), CD11c (clone: N418), CD19 (clone: 6D5), CD30 (Tnfrsf8; 
clone: mCD30.1), CD45 (clone: 30-F11), CD47 (clone: miap301), CD48 (clone: HM48-1), 
CD81 (clone: Eat-2), CD90.2 (clone: 30-H12), CD127 (clone: A7R34), CD152 (CTLA-4; 
clone: UC10-4B9), I-A/I-E (clone: M5/114.15.2), IL-5 (clone: TRFK5), KLRG1 (clone: 
2F1/KLRG1), NK1.1 (clone: PK136), Sema4A (clone: 5E3/SEMA4A), ST2 (clone: DIH9), 
TCRβ (clone: H57-597) and TCRγδ (clone: GL3) were purchased from BioLegend. 7AAD 
was obtained from BD Pharmingen, CD121b (IL1r2; clone: 4E2), Batf (clone: S39-1060) 
and Siglec-F (clone: E50-2440) from BD Biosciences and CD85k (gp49; clone: H1.1), 
Fixable Viability Dye eFluor 506, galectin-3 (Lgals3; clone: eBioM3/38), IL-13 (clone: 
eBio13A), IL17RB (IL-25R; clone: Munc33), Ki-67 (clone: SolA15) and Nur77 (Nr4a1) 
(clone: 12.14) from eBioscience. Cells were stained on ice with antibodies for surface 
molecules and the live/dead marker 7AAD and analysed on a LSRFortessa (BD 
Biosciences). Intracellular cytokine staining was performed after incubation for 5 h with 1 
μM ionomycin (Sigma-Aldrich), 50 ng ml−1 phorbol 12-myristate 13-acetate (Sigma-
Aldrich) and GolgiStop (BD Biosciences). Cells were then fixed and stained using the BD 
Cytofix/Cytoperm buffer set (BD Biosciences) per manufacturer’s instructions. Proliferation 
was assessed by Ki-67 staining after cell fixation and permeabilization using the Foxp3/
Transcription Factor Staining Buffer Set (eBioscience). Different cell types were identified 
by the following gating strategies: ST2+ ILCs (7AAD− 
CD45+CD4−Lineage−CD90.2+CD127+ST2+), T cells (7AAD−CD45+CD4+), B cells 
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(7AAD−CD45+CD19+), eosinophils (7AAD−CD45+CD11b+CD11clowSiglec-F+SSChigh), 
neutrophils (7AAD−CD45+CD11clowCD11b+Ly6G+CD11b+), alveolar macrophages 
(7AAD−CD45+CD11chighCD11bintermediate) and CD45− cells (7AAD−CD45−).
Lung analysis
Mice were euthanized and perfused with cold PBS. Where indicated, after perfusion, 
broncho-alveolar lavage (BAL) was obtained by injecting 1.5 ml cold PBS into the lungs via 
a secured tracheal cannula. BALF was centrifuged, and the supernatant was used for 
analysing cytokine levels and the cell pellet was resuspended, counted, and used for flow 
cytometry. Following BAL, lung lobes were dissected. The post-caval lobe was fixed in 
buffered formalin for histological analysis. Single cell suspensions of the remaining lung 
parenchymal tissue were prepared with the GentleMACS lung dissociation kit (Miltenyi 
Biotec) according to the manufacturer’s instructions. Where indicated, cells were diluted in 
10% Trypan Blue and viable cells counted using a hemocytometer.
Fluorescence-activated cell sorting of innate lymphoid cells
After dissociation, single cell suspensions were incubated with CD90.2 MicroBeads 
(Miltenyi Biotec) on ice and enriched for CD90.2+ cells by magnetic separation using LS 
columns according to the manufacturer’s protocol. CD90.2+ lung cells were then stained on 
ice with antibodies for sorting. ILCs were defined as 7AAD−CD45+CD90.2+CD1 
27+Lineage− (lineage markers: CD11b, CD11c, CD19, NK1.1, CD3ε, CD4, CD8a, TCRβ, 
TCRγδ) cells and sorted on a BD FACS Aria (BD Biosciences).
RNA-seq
For population (bulk) RNA-seq, sorted ILCs were lysed with RLT Plus buffer and RNA was 
extracted using the RNeasy Plus Mini Kit (Qiagen). Full-length RNA-seq libraries were 
prepared as previously described45 and paired-end sequenced (75 bp × 2) with a 150 cycle 
Nextseq 500 high output V2 kit.
For droplet-based 3′ end massively parallel single-cell RNA sequencing (scRNA-seq), 
sorted ILCs were encapsulated into droplets, and libraries were prepared using Chromium 
Single Cell 3′ Reagent Kits v2 according to manufacturer’s protocol (10× Genomics). The 
generated scRNA-seq libraries were sequenced using a 75 cycle Nextseq 500 high output V2 
kit.
For full-length scRNA-Seq, single ILCs were sorted into 96-well plates containing 5 μl TCL 
Buffer (QIAGEN) with 1% 2-mercaptoethanol, centrifuged and frozen at −80 °C. SMART-
Seq2 protocol was carried out as previously described23 with minor modifications in the 
reverse transcription step (M.S.K. and A.R., in preparation). cDNA was amplified with 22 
cycles and tagmented with one-eighth of the standard Illumina NexteraXT reaction volume. 
Single-cell libraries were pooled and paired-end sequenced (38 bp × 2) with a 75 cycle 
Nextseq 500 high output v2 kit.
All RNA-seq data represent pooled data from at least two distinct biological replicates.
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ILC in vitro culture
For in vitro experiments 5,000 ILCs per well were cultured in a 96-well round bottom plate 
with 20 ng ml−1 IL-7 (R&D Systems), 200 ng ml−1 IL-25 (R&D Systems) or 20 ng ml−1, 2 
ng ml−1 or 0.2 ng ml−1 IL-33 (BioLegend) with or without 1 μg ml−1 neuromedin U (US 
Biological). In some cases purified CD90.2+ lung cells were first labelled with CellTrace 
Violet (Thermo Fisher Scientific), then sorted as described above, and cultured for three 
days under the indicated conditions.
Histology
Following paraffin embedding, sections of the formalin-fixed lung lobe were stained by 
H&E staining. Tissue sections were scored by a histopathologist in a blinded manner for 
severity of lung inflammation according to the following scoring system: 0, normal; 1, very 
mild; 2, mild; 3, moderate; 4, severe.
Methacholine challenge
Airway hyper-responsiveness was determined as previously described28 using a flexiVent 
rodent ventilator (SciReq).
LacZ reporter assay
The Nmur1 null allele contains a LacZ reporter cassette. Single-cell suspensions of lung 
cells from Nmur1-LacZ+/− mice were stained with the FluoReporter lacZ flow cytometry kit 
(Thermo Fisher Scientific) according to the manufacturer’s protocol. Immediately after 
fluorescein di-V-galactoside (FDG) loading was stopped with 1.8 ml ice-cold medium, cells 
were stained with 7AAD and antibodies against surface markers and analysed by flow 
cytometry.
Quantitative real-time PCR
RNA was isolated using RNeasy Plus Mini Kit (Qiagen) and reverse transcribed to cDNA 
with iScript cDNA Synthesis Kit (Bio-Rad). Gene expression was analysed by quantitative 
real-time PCR on a ViiA7 System (Thermo Fisher Scientific) using TaqMan Fast Advanced 
Master Mix (Thermo Fisher Scientific) with the following primer/probe sets: Il5 
(Mm00439646_m1), Il13 (Mm00434204_m1), Il17rb (Mm00444709_m1), Nmur1 
(Mm04207994_m1), Nmur2 (Mm00600704_m1), Nmu (Mm00479868_m1) and Actb 
(Applied Biosystems). Expression values were calculated relative to Actb detected in the 
same sample by duplex qPCR.
Cytokine quantification
Cytokine concentrations in BAL fluid, lung and supernatant of in vitro ILC cultures were 
analysed by the LegendPlex Mouse Th Cytokine Panel (13-plex) (BioLegend) according to 
the manufacturer’s instructions and analysed on a FACS Calibur (BD Biosciences).
T cell in vitro culture
CD4+ T cells were isolated as described previously46 and sorted for naive T cells 
(CD4+CD62L+CD44low) on a FACS Aria. Naive T cells were cultured in the presence of 
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plate-bound anti-CD3 (1 μg ml−1; Bio X Cell) and anti-CD28 (1 μg ml−1; Bio X Cell) 
antibodies. TH2 cells were generated by addition of 20 ng ml−1 IL-4 (Miltenyi Biotec) and 
20 ng ml−1 anti-IFNγ (Bio X Cell) antibody. On day 3 of in vitro differentiation, PBS, 200 
ng ml−1 IL-33 (BioLegend) or 100 ng ml−1 IL-25 (R&D Systems) were added to the T cell 
culture either with or without 1 μg ml−1 NMU (US Biological). After 2 additional days, 
RNA was isolated.
Nodose/jugular and dorsal root ganglion isolation and cultures
Nodose/jugular ganglion and dorsal root ganglia (DRG) were dissected from mice and 
dissociated in 1 mg ml−1 collagenase A with 3 mg ml−1 dispase II (Roche Applied Sciences) 
in HEPES buffered saline (Sigma) for 60 min at 37 °C. For some experiments, cells were 
then lysed in RLT Plus buffer and RNA was isolated using the RNeasy Plus Mini Kit 
(Qiagen). For the purposes of cell culture, the DRG cell suspension was then triturated with 
glass pasteur pipettes of decreasing size, followed by centrifugation over a 12% BSA 
(Sigma) gradient. After centrifugation, the top layer of neuronal debris was discarded and 
the DRG pellet was resuspended in neurobasal (NB) media containing B-27 and penicillin/
streptomycin (Life Technologies). DRGs were then plated on laminin-coated 96-well culture 
dishes in NB media with B27, 50 ng ml−1 nerve growth factor (NGF) and penicillin/
streptomycin. The next day the cells were washed with PBS before addition of fresh NB 
media containing B-27, NGF and penicillin/streptomycin. DRG cultures were stimulated 
with 200 ng ml−1 IL-13 for 30 min, at which time RNA was isolated for qPCR analyses.
Immunofluorescence microscopy
Mice were perfused with 37 °C PBS via the heart. The lungs were extracted and inflated via 
the trachea with 4% low melting agarose (16520-100; Invitrogen) and fixed in 4% PFA on 
ice for 1 h. The lungs were embedded in agarose for vibratome cutting (Leica). 100-μm lung 
slices were blocked first with the mouse on mouse blocking reagent (Vector Laboratories) 
and subsequently with 5% goat and donkey serum (Jackson ImmunoResearch) in PBS/0.1% 
Triton X-100. Tissue was stained for rat anti-CD3ε (17A2; BioLegend), hamster anti-
KLRG1 (2F1; eBioscience) and mouse anti-SNAP-25 (SMI81; BioLegend) overnight at 
4 °C shaking. After washing in PBS, tissues were incubated at room temperature for 1 h in 
in PBS/0.1% Triton X-100 containing goat anti-rat-AF555, goat anti-hamster-AF647, or 
goat anti-mouse IgG1-AF488 (all ThermoFisher Scientific) and then washed again. Images 
were acquired with an inverted Nikon Eclipse Ti microscope (Nikon). Z-stacks were 
acquired and converted into all-in-focus images using the Extended Depth of Focus (EDF) 
plug-in (NIS-Elements). Distances of KLRG1+CD3ε− cells to the closest SNAP-25+ nerve 
fibre were measured using the NIS-Elements software.
Statistical analysis of functional data
No data were excluded from analysis. Prism 7 (GraphPad Software) was used to perform 
two-tailed t-test and ordinary one-way or two-way ANOVA with Tukey’s multiple 
comparisons test on datasets for which statistical significance is indicated (except the RNA-
sequencing data). All figures of functional data show mean ± s.e.m.
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P values in transcriptomic analysis
For certain types of numeric computations, the smallest P value that R can report is <2.2 × 
10−16.
Analysis of droplet-based scRNA-seq samples: initial QC
Gene counts were obtained by aligning reads to the mm10 genome using CellRanger 
software (v1.2 for data from alarmin-treated and NMU-treated mice, v1.3 for data from 
HDM-treated mice) (10× Genomics), with the genome re-annotated at the 3′ end of Nmur1 
(see main text). To remove doublets and poor-quality cells, cells were excluded from 
subsequent analysis if they were outliers in their sample of origin in terms of number of 
genes, number of unique molecular identifiers (UMIs), and percentage of mitochondrial 
genes (Extended Data Fig. 1b, c). The number of UMIs per cell and number of genes 
expressed per cell are tightly correlated with condition (Extended Data Fig. 1c), probably 
due to the effect of proliferation on transcript numbers. Sample-specific cut-offs ranged from 
626–2,483 genes per cell for a PBS-treated sample to 1,502–5,260 genes per cell for an 
IL-33 treated sample. At least 92% of cells were retained for each sample.
To further estimate and remove technical variability from the overall increased variability 
across replicates in group C (defined below), additional QC measures were taken (Extended 
Data Fig. 10a, b). UMI and gene saturation were estimated independently for each cell by 
subsampling a fraction of the total number of reads, with replacement, across a range of 
fractions (0.02 to 0.98, in 0.02 increments). For each subsample, we calculated the number 
of UMIs and transcripts detected. The sampling procedure was repeated ten times, and the 
values were used to estimate saturation limits for UMI/genes by nonlinear fitting of the 
following saturation function: y = ax/(b + x) + c. Cells were removed if they were outliers 
with respect to estimated saturation for either genes or UMIs. Cells were also removed if 
they were outliers in terms of the ratio or relative difference of the total number of UMIs 
with the number of unique UMIs. After all QC, 73–83% of cells in each of these samples 
were retained.
Parts of the subsequent analysis used the R package Seurat47, version 1.4.0.7, which 
includes sparse matrix support for large datasets. To normalize gene counts while accounting 
for widely varying UMI counts among conditions, we used a scaling factor reflecting the 
expected number of UMIs in each condition. Let wc,i be the mean number of UMIs per cell 
in condition c, batch i. Seurat’s LogNormalize() function was called on cells from condition 
c with the scale factor argument set to:
We refer to the output values as logTPX (as opposed to the default logTPM).
The 63,152 high-quality cell profiles were combined into three (non-exclusive) groups:
• Group A (24,187 cells): cells stimulated with PBS (9,623 cells), IL-25 (6,849 
cells), or IL-33 (7,715 cells).
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• Group B (35,542 cells): cells stimulated with PBS (9,623 cells), NMU (9,698 
cells), IL-25 (6,849 cells), or IL-25 combined with NMU (9,372 cells).
• Group C (21,895 cells: cells from wild-type mice stimulated with PBS (5,393 
cells) or HDM (6,280 cells), as well as Nmur1-knockout mice stimulated with 
PBS (4,191 cells) or HDM (6,031 cells).
To verify that the dataset consists of ILCs, we checked the raw counts for the expression of 
major markers of other immune cell groups (Extended Data Fig. 1j). For subsequent 
analysis, genes expressed in less than 0.1% of cells were excluded.
Analysis of droplet-based scRNA-Seq samples: signature scores
We calculated signature scores as the log of the geometric mean of the TPX values for the 
genes in the signature. That is, let S be a set of m genes defining a signature, and for any 
gene g in S and a given cell, let xg be the expression of g in the cell in TPX. Then the 
signature score for that cell is calculated as
which is equivalent to the arithmetic mean of the logTPX values. Actual expression values, 
rather than centred or z-scored expression values were used. For several of our signatures, 
centreing (or z-scoring) expression values before computing signatures leads to misleading 
scores that are close to 0 across the whole dataset, though the corresponding gene expression 
is high. This is in part due to ILC2s composing the majority of the cells, and hence genes 
that are highly expressed by ILC2s lack sufficient variance over the dataset to be useful in a 
mean-centred signature.
We also did not replace these scores with a statistical comparison of them to randomized 
signatures selected from a null distribution (in contrast to our other studies20,45). Owing to 
the varying proliferative responses in our cells, it is difficult to find a true null set of 
signatures, even after matching genes for dataset-wide mean and variance profiles. Signature 
scores are thus calculated in a way that is independent of the expression levels of unrelated 
genes in the same cell, and may be interpreted as similar to, though less noisy than, single-
gene expression values.
The ILC subset signatures (ILC1, 2, 3 as used in Figs 1c, 5b, Extended Data Figs 1d–g, k, 
3b–e, 10c–e) were curated based on established markers for ILC subsets (Supplementary 
Table 2). The proliferation signature was created by combining our previously published 
gene signatures19,20 that define G1–S and G2–M phases (Supplementary Table 2). For both 
ILC subset and proliferative signatures, all genes contribute positively to the signature score. 
For the inflammatory ILC2 signature, differentially expressed genes contribute positively to 
the score if they are upregulated in ILC2s from wild-type mice after HDM stimulation 
relative to PBS, and negatively otherwise (Supplementary Table 1).
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Analysis of droplet-based scRNA-Seq samples: assigning ILC type
ILC signatures were used to assign each cell to one of the following categories: ILC1, ILC2, 
ILC3, ‘mixed’ (scoring highly for multiple ILC types), and ‘none’ (not scoring highly for 
any ILC type) (Supplementary Table 2). The frequency of mixed type ILCs (2.6%) is 
comparable to the expected doublet rate (3–4%). Based upon the dip in the bimodal 
distributions of ILC subset signature scores (Extended Data Figs 1d, 3b, 10c, d), the 
minimum score for assignment to a given category was set to 0.08. To be uniquely assigned 
to a category, the ratio of the highest score to the next highest score was required to be at 
least 1.25. The analysis is not sensitive to the specific ratio threshold choice of 1.25; that 
selection was made to balance the trade-off between the purity of the transcriptional profile 
of cells assigned to one of the three ILC subtype populations, and the number of cells called 
as mixed.
To test the strength of association between ILC type and treatment conditions, we used the R 
package nnet, version 7.3-12, to do a multinomial logistic regression on the ILC type, with 
replicate and condition as predictors.
Analysis of droplet-based scRNA-Seq samples: PCA, clustering, and tSNE
Variable genes were then selected using the MeanVarPlot function in Seurat with the 
x.low.cutoff and y.cutoff parameters set to 0.05 and 0.7, respectively, resulting in gene sets 
of size 774 (group A), 723 (group B), and 475 (group C). PCAFast was run on mean-centred 
variable genes to compute a limited number of PCs. To select the number of PCs to include 
for subsequent analysis, we estimated the number of eigenvalues larger than would be 
predicted by a null distribution for random matrices (Marchenko-Pastur law), and also 
assessed the decrease in marginal proportion of variance explained with larger PCs. The top 
22 (groups A, B) and 13 (group C) PCs were included for subsequent analysis. We 
confirmed that the resulting analyses were not particularly sensitive to this exact choice.
The cells were clustered via Seurat’s FindClusters function, which optimizes a modularity 
function on a k-nearest-neighbour graph computed from the top eigenvectors. After a range 
of cluster resolution parameters were tested, 0.6 (groups A and B) and 0.5 (group C) were 
selected because resulting clusters captured major, condition-related divisions, known 
subgroups, and statistically validated transcriptional distinctions of interest, while avoiding 
subdivisions of relatively uniform parts of the data.
To visualize the data, tSNE plots were created by calling Seurat’s RunTSNE function, with 
the dims.use parameter set to the selected number of PCs and the do.fast parameter set to 
TRUE. A number of perplexity para meter choices were evaluated before selecting 100 
(group A) and 50 (groups B and C). These perplexity settings produced tSNE plots that 
reflected the cluster structure found independently of tSNE, without introducing extreme 
artefacts. tSNE plots of cells separated by batch indicate that experimental batches appear to 
have a rela tively minor impact on the PCA and clustering (Extended Data Figs 1h, 9b, 10b).
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Analysis of droplet-based scRNA-seq samples: differential gene expression
To avoid spurious results due to cells in different conditions or clusters having vastly 
different amounts of mRNA, differential expression (DE) analysis accounted for the varying 
number of transcripts in each condition. We fit raw counts to a mixture of generalized linear 
models that include covariates for the log of the number of UMIs in a cell, as well as a 
categorical variable for the batch. Specifically, we fit a zero-inflated negative binomial 
model using the zeroinfl function48 from the pscl R package49, version 1.4.9. The zero-
inflated negative binomial model combines a count component and a point mass at zero, 
which is relevant for scRNA-seq data where zero values are inflated owing to the technology 
not capturing expressed genes, particularly those with low expression11. The model requires 
a substantial amount of data to fit, making it well suited to data generated by massively 
parallel methods. As an alternative to the zero-inflated negative binomial, we also performed 
a logistic regression by fitting a generalized linear model using the binomial family with a 
logit link, with the same covariates.
DE tests included the following models: (1) a cluster-based model with indicator coefficients 
for each cluster except the reference PBS-dominated cluster (groups A, B, and C); (2) a 
condition-wide model with indicator coefficients for each condition (with the PBS condition 
as reference) (groups A, B, and C); and (3) a direct comparison of IL-25 versus IL-33, with 
IL-33 as reference (group A); (4) a condition-based model with indicator coefficients for 
NMU and IL-25, and an additional interaction term (with the PBS condition as reference) to 
detect non-additive effects (group B); (5) a direct comparison between IL-25 combined with 
NMU and IL-25, with IL-25 as reference (group B). In group C, we restricted the DE 
analysis to the cells transcriptionally classified as ILC2s, in order to identify difference in 
these particular cells, without the analysis being driven by the change in relative proportions 
of ILC1s and ILC3s compared to ILC2s after HDM treatment.
Many cell-cycle genes and ribosomal protein genes are differentially expressed across 
conditions and clusters, particularly if there is a difference in proliferation. To detect other 
differentially expressed genes as well, before ranking DE results, we removed ribosomal 
protein genes and (in all cases except group C, where it was not needed) the genes in the 
proliferation signature (Supplementary Table 2).
DE tests report coefficients and associated P values for each variable of interest (for 
example, cluster or condition), separately for each model component. To rank the results for 
any given model, we created a list of differentially expressed candidate genes that are 
detected in at least 10% (15% for group C) of the cells in one of the groups in the model and 
have a coefficient for a term of interest with absolute value at least 0.5 (0.75 for group C) 
and corresponding FDR-adjusted P value <1 × 10−20 for condition-wide DE, <1 × 10−6 for 
cluster DE, for at least one component. We ranked these candidates by lowest P value and 
also by largest absolute value of coefficient. The top 25 genes (top 5, 5 and 3 genes for 
cluster models in groups A, B and C, respectively) genes according to each ranking were 
reported, with a minimum of 1–2 genes, if available, selected from each of the set of 
candidates with positive coefficients and the set with negative coefficients. These genes are 
reported according to the condition or cluster for which they were ranked highly, and the 
sign reported is ‘plus’ (‘minus’) if that condition or cluster has a higher (lower) expression 
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by both fraction of cells expressing and level of expression than the reference, or if these are 
discordant then the sign is reported as ‘NA’ (Supplementary Table 1).
We curated a representative selection from the highest ranked results to represent, in Fig. 1f, 
common, distinctive patterns across clusters in group A, and, in Fig. 4h, patterns that 
distinguish IL-25 combined with NMU from the other conditions in group B and highlight 
nonlinear interactions between NMU and IL-25. To create the inflammatory ILC2 signature 
(Fig. 5c–e) we used the top-ranked genes differentially expressed between HDM and PBS 
treatments in ILC2s only in wild-type mice, as well as those differentially expressed in 
HDM- and ILC2-dominated clusters (5 and 6) in this dataset. The signature genes are 
reported with the sign positive if the respective condition or cluster has higher expression 
than the reference for that model (Supplementary Table 1).
To more broadly compare differentially expressed genes between HDM and IL-25 combined 
with NMU datasets, we constructed one gene set for IL-25 combined with NMU by taking 
the top differentially expressed genes for all models and comparisons in group B in which 
there is a coefficient for the condition IL-25 combined with NMU or a coefficient for a 
group or cluster to which cells treated with IL-25 combined with NMU contribute (clusters 
2, 6–11) (Supplementary Table 1). We then performed the analogous procedure in the HDM 
data (including clusters 1–2 and 4–7) (Supplementary Table 1). Using as the null set the 
12,719 genes shared between groups B and C, we used Fisher’s exact test to determine the 
significance of the overlap of 23 genes between the 156 genes from the IL-25 combined with 
NMU gene set (151 of which are in the null set) and the 85 genes from the HDM data (all of 
which are in the null set) (P < 1.64 × 10−25).
Analysis of SMART-Seq2 plate-based scRNA-seq data
Reads were aligned to mm10 using Kallisto50 quant, version 0.42.3. The R package 
tximport51, version 1.2.0, was used to convert the output to gene counts and traditional TPM 
values. Because of the variability in read counts per cell across plates, even from the same 
condition, as well as in the number of genes per cell across conditions, QC was performed 
for each of eight plates individually in order to remove cells that were outliers or too low 
with respect to either measure (Extended Data Fig. 3a). Out of 752 cells, 606 cells met QC 
criteria (234 from control, 152 from IL-25-treated mice, and 220 from IL-33-treated mice), 
and the number of genes per cell in this set ranged from 1,625 to 6,375. Genes that were not 
expressed with log(TPM) > 2.5 in at least two cells were removed from further analysis. 
Subsequent analysis proceeded analogously to the droplet-based RNA-seq analysis, with 
parameter settings that reflected both the wider dynamic range of expression and much 
smaller cell numbers. The minimum ILC signature score required in ILC type assignment 
was 0.3. Variable genes were identified by running MeanVarPlot with x.low.cutoff = 0.1, 
y.cutoff = 1.5, and x.high.cutoff = 10, resulting in a set of 519 genes. PCA was performed on 
the mean-centred expression of variable genes, with 9 PCs chosen for the subsequent 
clustering analysis (resolution parameter 0.6). RuntSNE was called with the default 
perplexity value of 30.
The DE analysis for plate-based data followed the structure of the droplet-based analysis but 
used only logistic regression, with both a condition-based model and a cluster-based model. 
Wallrapp et al. Page 17
Nature. Author manuscript; available in PMC 2017 December 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
To rank the results for each model, we created a list of differentially expressed candidate 
genes that are detected in at least 30% of the cells in one of the groups in the model and have 
a coefficient for a term of interest with an absolute value at least 1.0 (for condition-based 
models) or 1.5 (for cluster models) and corresponding FDR-adjusted P values <1 × 10−4 (for 
condition-based models) or <1 × 10−5 (for cluster models). We ranked the candidates by 
lowest P value and by largest absolute value of coefficient. The top 40 genes (for condition 
model) or 3 genes (for cluster model) according to each ranking were reported, with a 
minimum of 10 genes (for condition model) or 1 gene (for cluster model), if available, 
selected from each of the set of candidates with positive coefficients and the set with 
negative coefficients (Supplementary Table 1). To create the plot in Fig. 2c, we took a high-
ranked illustrative subset of these genes.
To compare plates and droplets, we took as the null set all genes (11,117 genes) detected in 
both group A from droplet-based data and in plates. For the PCA comparison, we took the 
union of the highest and lowest 10 (group A) or 20 (plates) genes for the PCs used in each 
analysis (141 genes from droplet-based data, 202 genes from plate-based data, 66 genes in 
the intersection), and used Fisher’s exact test to determine significance (P < 3.74 × 10−80). 
For the comparison of differentially expressed genes, we used the previously computed sets 
of top-ranked DE genes for group A (219 genes) and for the plate data (72 genes), and again 
used Fisher’s exact test to determine significance of the overlap (P < 3.91 × 10−25).
Re-annotation of the 3′ UTR of Nmur1
Initially, Nmur1 had essentially no detected expression in the droplet-based scRNA-seq data, 
though many reads align to a region just downstream of the Nmur1 3′ UTR annotation 
(Extended Data Fig. 4b). To explore the basis of this discrepancy, we aligned long (75 bp) 
paired-end reads from full-length RNA-seq of population samples that included cells from 
all three stimulation conditions (only those from IL-25 shown). Many read alignments 
bridge the annotated Nmur1 transcript and the region downstream where droplet-based 3′ 
reads align (Extended Data Fig. 4b), evidence that Nmur1 has isoforms longer than the 
annotated transcript. We re-annotated the transcriptome, moving the 3′ end from 86,386,242 
to 86,384,000, and realigned the droplet-based scRNA-seq data, resulting in a robust 
increase in frequency of detection of Nmur1. All droplet-based scRNA-seq data shown in 
this maunscript was aligned to this re-annotated transcriptome.
Wallrapp et al. Page 18
Nature. Author manuscript; available in PMC 2017 December 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Extended Data
Extended Data Figure 1. Massively parallel scRNA-seq of lung ILCs
a, Schematic of experimental method for in vivo activation of ILCs. b, c, Quality measures. 
b, Scatter plots show for each cell the relation between the number of UMIs (nUMI, x axis) 
and the number of genes (nGene, y axis). Cells are coloured according to whether they are 
included (grey) or excluded (red) from further analysis by these measures. c, Box plots show 
the distribution of the number of unique genes (y axis, left), UMIs (y axis, middle) and per 
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cent of normalized expression from mitochondrial genes (y axis, right) in each treatment and 
replicate (rep; x axis). White diamond indicates the mean. d–g, ILC classification by 
signatures. d, Density plots show the distributions of ILC subset signature scores (x axis) for 
ILC1 (left), ILC2 (middle) and ILC3 (right) in each of three treatments (control, grey; IL-25, 
yellow; IL-33, blue). Dashed lines mark the cut-offs used in the ILC classification for each 
signature. e, Bar plots of the proportion of 24,187 cells (y axis) classified in each treatment 
(x axis) based on transcriptional signatures of known ILC subsets as ILC1 (green), ILC2 
(pink), ILC3 (blue), mixed (yellow, scoring for two or more signatures), or none (grey, 
scoring for none of the three signatures). f, Bar plots show the number of ILCs (y axis) 
classified to each subset (colour code) in the PBS, IL-25 or IL-33 conditions (x axis). g, 
Expression of key ILC marker genes. Violin plots show the distribution of expression levels 
(logTPX, y axis) of each of 12 ILC marker genes (marked on top) in cells classified in each 
subtype (rows) in each treatment (x axis). h, Cell groupings are independent of batch. tSNE 
plot of cells (as in Fig. 1a) from replicate 1 (left plot) and replicate 2 (right plot), coloured 
by condition. i, Expression of key genes. tSNE is coloured by the relative expression of the 
indicated genes. j, Gene expression for marker genes of ILCs and other immune cell types. 
For each gene (columns) in each cluster (rows), the proportion of cells in the cluster 
expressing the gene (dot size) and the relative mean log nUMI of expressing cells (colour) is 
plotted. k, l, Cluster composition. Bar plots show the number of cells (y axis) from each ILC 
type (k) and condition (l) in each cluster (x axis). m, Validation of expression patterns 
identified by scRNA-seq using flow cytometry. In each histogram, the expression of proteins 
encoded by genes identified with scRNA-seq on ILCs from mice treated with PBS (grey, 
closed) versus one of the alarmins IL-25 or IL-33 (blue, closed) is shown, as well as a 
fluorescence minus one (FMO) control (blue, dashed). Numbers indicate the mean 
fluorescence intensity of the marker in PBS (grey) or condition (blue) or, for CTLA4 and 
MHC class II, the frequency of cells positive for the marker in PBS (grey) or condition 
(blue). Data are representative of at least two individual experiments.
Extended Data Figure 2. Alarmin-induced ILC proliferation in vitro
ILCs were labelled with CellTrace Violet and cultured in vitro under the indicated 
conditions. After 3 days, proliferation was analysed by flow cytometric analysis of CellTrace 
Violet dilution. The frequency of non-proliferating ILCs is indicated. Data are representative 
of two individual experiments.
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Extended Data Figure 3. Plate-based scRNA-seq of lung-resident ILCs
a, Quality measures. Scatter plots for each plate showing the total number of read counts per 
cell (x axis) and number of unique detected genes (y axis) in each cell. Dashed lines indicate 
cut-offs for passing quality control. Only cells in the central quadrant were retained for 
analysis. b–e, ILC subset classification. b, ILC signature score distributions. Density plots 
show the distributions of ILC subset signature scores (x axis) for ILC1 (top), ILC2 (middle) 
and ILC3 (bottom) in each of three treatments (control, grey; IL-25, yellow; IL-33, blue). 
Dashed lines mark the minimum score cut-off used in the ILC classification for each 
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signature. c, Expression of key ILC marker genes. Violin plots show the distribution of 
expression levels (logTPM, y axis) of each of 12 ILC marker genes (marked on top) in cells 
classified in each subtype (rows) in each treatment (x axis). d, Distinct cell subsets by ILC 
expression profile. tSNE plot shows individual cells (dots) in a nonlinear reduced 
representation of the top 9 PCs, with cells coloured by ILC subset. e, Composition by 
treatment condition. Bar plots show the proportion of each ILC subtype (y axis) in each 
treatment condition (x axis).
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Extended Data Figure 4. Accurate detection of Nmur1 from massively parallel 3′end scRNA-seq 
requires cell-type specific annotation
a, Comparison of gene expression estimates from plate-based and droplet-based scRNA-seq. 
Scatter plots show for each gene (dot) the fraction of cells expressing it according to plate-
based scRNA-seq (x axis) and droplet-based scRNA-seq (y axis) in the PBS (top) and IL-25 
(bottom) conditions. Of the differentially expressed genes in the plate-based data that are 
expressed in a substantially different proportion of cells compared to droplet-based data 
(red), Nmur1 and Rapgef4 are among the highest ranked and are only detected in the plate-
based data. b, Re-annotation of the Nmur1 locus by RNA-seq and assembly. Shown is a 
window of approximately 7 kb around the annotated Nmur1 locus on chromosome 1 (top) 
along with read alignments to that region from either droplet-based 3′scRNA-seq (top, 55-nt 
reads) or from population (bulk) RNA-seq of ILCs (bottom, 75-nt reads). The Refseq 
annotation of Nmur1 (top blue track) does not extend to the 3′ end of the transcript, as 
defined by either the scRNA-seq reads (10× Nmur1 extended; middle blue track) or by a 
transcriptome reassembly from bulk RNA-seq (StringTie reassembled; bottom blue track). c, 
Corrected annotation recovers Nmur1. Histogram shows the distribution of expression levels 
of Nmur1 in single cells based on droplet-based scRNA-seq data when expression was 
calculated by aligning reads with the original RefSeq annotation (left), the scRNA-seq read-
based extended annotation (middle) or the reassembled transcript annotation from bulk 
RNA-seq (right). d, Rapgef4 locus correctly annotated. Shown is a plot for Rapgef4, 
arranged as in b. The 3′ annotation in the RefSeq annotation agrees with the observed end 
from bulk RNA-seq.
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Extended Data Figure 5. Expression of Nmur1 and Nmur2 in lung-resident immune cells
a, Minimal expression of Nmur1 on in vitro differentiated TH2 cells. Bar chart shows Nmur1 
mRNA levels by qPCR in both TH2 cells differentiated under the indicated conditions in 
vitro, and in freshly isolated ILCs. Data points represent technical replicates (n = 2). b, 
Nmur2 is not expressed by lung-resident immune cells, including ILCs. Bar chart shows 
Nmur2 mRNA levels by qPCR for the indicated cell types, which were sorted from mice 
either at steady state (PBS) or after HDM challenge. The mean of technical replicates is 
shown (n = 2). c, Summary graph of the flow cytometry data, of which a representative is 
shown in Fig. 2e. Plot shows the frequency of NMUR1+ cells in different cell populations 
from Nmur1-LacZ reporter mice as assayed by flow cytometry. Data points represent 
individual mice (n = 3). d, Nmur1-LacZ β-galactosidase activity reveals ILC-specific 
NMUR1 expression. Representative histograms show the distribution of expression of 
NMUR1 in the indicated cell types as determined by flow cytometry in cells isolated from 
wild-type (red) and Nmur1-LacZ heterozygous (blue) mice. The frequency of Nmur1-LacZ-
positive cells is indicated. e, NMUR1 is preferentially expressed by ST2+ ILCs. The 
expression of ST2, IL-17RB and NMUR1 was analysed by flow cytometry, and the 
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frequency of NMUR1+ ILCs within the indicated populations is shown. Each data point 
reflects an individual mouse (n = 4 for PBS and IL-33; n = 3 for IL-25). All panels represent 
one of two individual experiments, mean is indicated, error bars represent s.e.m.; *P < 0.05 
by two-tailed t-test.
Extended Data Figure 6. ILCs and neurons are in proximity in the lung, and NMU is expressed 
by dorsal root ganglion neurons
a, Representative image (left) of lung sections stained for the neuronal marker SNAP-25 
(green), KLRG1 (red), and CD3ε (blue). Arrows indicate KLRG1+ CD3ε− cells in close 
proximity to SNAP-25+ nerve fibres. Scale bar, 100 μm. Bar plot (right) shows the frequency 
of ILCs (x axis) within indicated distances (y axis) of SNAP-25+ nerve fibres. All 
KLRG1+CD3ε− cells in the field of view were counted, and the distances between ILCs and 
the closest SNAP-25+ nerve fibre were measured (3–5 lung sections per mouse, n = 3 mice). 
Data are representative of three independent experiments with similar results. b, c, NMU is 
expressed in thoracic dorsal root ganglion (DRG) neurons. NMU expression was examined 
by qPCR. b, NMU expression in the nodose/jugular ganglion and DRG ex vivo. Data points 
represent technical replicates (n = 2). c, NMU expression in DRG neurons stimulated in 
vitro with IL-13. Data points represent two technical replicates from each of six biologic 
replicates. All panels are representative of at least two individual experiments, mean is 
indicated, error bars represent s.e.m.; *P < 0.05 by two-tailed t-test.
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Extended Data Figure 7. NMU induces minimal lung inflammation in the absence of alarmins
a, NMU does not alter in vitro expression of type 2 cytokines in T cells. Expression of Il5 
and Il13 is similar in TH2 cells cultured with or without NMU, as assessed by qPCR. b, c, 
ILCs were isolated from naive mice and cultured in vitro with the indicated stimuli. b, ILCs 
cultured in vitro have markedly enhanced Il5 and Il13 mRNA expression in response to 
combination of NMU and IL-25, as measured by qPCR. c, IL-33-induced IL-5 and IL-13 
secretion is enhanced by NMU, as determined by LegendPlex. Data points represent 
technical replicates, and the mean is indicated. d–h, NMU alone induces minimal allergic 
lung inflammation. d, Schematic of experimental method for activation of ILCs with NMU 
in vivo. e, Il5 and Il13 expression was determined in lung mononuclear cells by qPCR. f, 
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The concentration of IL-5 and IL-13 protein in BALF was analysed by LegendPlex. g, h, 
Eosinophil frequencies in lung parenchyma (g) and BALF (h, left), and BALF eosinophil 
numbers (h, right), as determined by flow cytometry. Data points correspond to individual 
mice (n = 3). i, The combination of IL-25 combined with NMU markedly enhanced Il5 (top) 
and Il13 (bottom) mRNA expression in lung mononuclear cells, as measured by qPCR. j, 
NMU and IL-25 synergize to promote tissue eosinophilia. Eosinophil frequency (top) and 
number (bottom) in lung parenchyma was assessed by flow cytometry. Data points 
correspond to individual mice (PBS, n = 3; IL-25, n = 9; IL-25 combined with NMU, n = 7). 
For all panels, data are representative of at least two individual experiments, mean is 
indicated, error bars represent s.e.m.; *P < 0.05 by two-tailed t-test.
Extended Data Figure 8. Phenotype of Nmu-knockout mice
a–c, ILC frequency and function are not altered in the absence of NMU in steady state. 
Lung-resident ILCs isolated from wild-type and NMU-deficient mice were analysed by flow 
cytometry. a, b, The frequency of ILCs (among CD90+ cells, a) and expression of KLRG1 
and ST2 on ILCs (b) are unchanged in Nmu-knockout mice compared to control mice. c, 
Frequency of IL-5- and IL-13-producing ILCs in Nmu-knockout mice is comparable to that 
of control mice. Each data point corresponds to an individual mouse (wild-type, n = 4; Nmu-
knockout, n = 5). d–f, Analysis of BALF and T-cell responses in Nmu-knockout mice after 
HDM challenge. d, BALF cell numbers (left) and the frequency of eosinophils (right) were 
analysed after HDM challenge in Nmu-knockout mice. Total cell numbers (wild-type, n = 
15; Nmu-knockout, n = 13) and eosinophil frequency are unchanged in Nmu-knockout mice 
(n = 17) compared to wild-type mice (n = 21). e, Increased lung-infiltrating CD4 T cells in 
the absence of NMU. The frequency of lung-infiltrating T cells was determined by flow 
cytometry after HDM challenge (wild-type, n = 15; Nmu-knockout, n = 13). f, Intact TH2 
response in the absence of NMU. Expression of IL-5 and IL-13 by CD4 T cells was 
analysed by flow cytometry following HDM challenge. Each data point represents an 
individual mouse (wild-type, n = 5; Nmu-knockout, n = 5). All panels are representative of 
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at least two individual experiments. For all panels, mean is indicated, error bars represent 
s.e.m.; *P < 0.05 by two-tailed t-test (a–d, f) or one-way ANOVA (e).
Extended Data Figure 9. Massively parallel, droplet-based scRNA-seq of ILCs from mice treated 
with NMU or IL-25 combined with NMU
a, Quality measures. Bar plots show the distribution of the number of unique genes (y axis, 
top), per cent of reads from mitochondrial genes (y axis, middle) and number of UMIs (y 
axis, bottom) in each treatment and replicate (x axis). White diamond indicates the mean. b, 
Grouping of ILCs is independent of batch. tSNE plots (as in Fig. 4a) of cells from replicate 1 
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(top) and replicate 2 (bottom) coloured by condition. c, Faceted tSNE plot of ILCs from all 
alarmin and NMU treatments, coloured by condition, shows that IL-25 combined with NMU 
and IL-33 induce partially overlapping transcriptional responses. d, e, Cluster composition. 
d, Bar plot shows the proportion of ILCs from each condition in each cluster. e, Bar plot 
shows the number of cells from each condition in each cluster. f, g, IL-25 combined with 
NMU promotes ILC proliferation. f, The frequency of Ki-67+ ILCs was determined by flow 
cytometry in mice treated with IL-25 or IL-25 combined with NMU. Data points represent 
individual mice (IL-25, n = 8; IL-25 combined with NMU, n = 6). g, Violin plots show the 
distributions of the proliferation signature scores (y axis) for the cells in each cluster (x axis) 
(white diamond, mean; lines, first and third quartiles). Proliferation scores in cluster 11 are 
significantly higher than those in the other clusters dominated by IL-25 combined with 
NMU (8, 9 and 10) (t-test, P < 2.2 × 10−16). h, IL-25 combined with NMU enhances 
expression of Il17rb in mononuclear lung cells, as shown by qPCR. Data points represent 
individual mice (PBS, n = 3; IL-25, n = 9; IL-25 combined with NMU, n = 7). i, Validation 
of expression patterns identified by scRNA-seq using flow cytometry. Expression levels for 
proteins encoded by genes identified by scRNA-seq on ILCs from mice treated with PBS 
(grey, closed histogram) versus one of the treatments (blue, closed histogram), as well as an 
FMO control (dashed open histogram) is shown. Numbers indicate the mean fluorescence 
intensity of the respective marker or, if a gate is indicated, the frequency of positive ILCs in 
PBS (grey) and in the indicated condition (blue). j, Distinct patterns of expression of key 
differentially expressed genes across clusters. Violin plots show the expression levels in 
logTPX (y axis) for the indicated genes across the cells in each cluster (x axis) (white 
diamond, mean; line, median). k, NMUR1 is downregulated after activation with IL-25 
combined with NMU. The frequency of NMUR1+ ILCs (y axis) in each condition among 
ILCs isolated from mice treated with the indicated stimuli is shown. Dots represent 
individual mice (n = 4, except for IL-25, where n = 3). l, m, Increased frequency of 
KLRG1hiST2− inflammatory ILC2s (iILC2s) after treatment with IL-25 combined with 
NMU. l, Frequency of iILC2s (of total ILCs) isolated from mice after different treatments. 
Dots represent individual mice (n = 4, except for IL-25, where n = 3). m, Representative 
flow cytometry plots of ST2 and KLRG1 expression on ILCs for the indicated conditions. 
For panels f, h k, l, mean is indicated and error bars represent s.e.m.; *P < 0.05 by two-tailed 
t-test (f) or one-way ANOVA (h, k, l).
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Extended Data Figure 10. Transcriptional analysis by massively parallel scRNA-seq of ILCs 
from wild-type and Nmur1-knockout mice during airway inflammation
a, Quality measures. The top row shows the distributions of the number of genes (log scale, 
x axis, left histogram) and UMIs (log scale, x axis, centre histogram) per cell and their 
relation (scatter plot, right) in the aggregated data. The middle row shows the distributions of 
the estimated saturation for UMIs (x axis, left histogram) and genes (x axis, middle 
histogram) per cell, as well as the ratio of the number of unique UMIs to total number of 
UMIs per cell (x axis, right histogram), for a representative sample. The bottom row shows 
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the distribution of the relative difference of the total number of UMIs and number of unique 
UMIs (x axis, left histogram), and the relation between the number of UMIs and number of 
genes (scatter plot, right), for the same representative sample. Dashed lines show lower and 
upper cut-offs used. Outlier cells (red dots, scatter plot) were also removed. b, Minor batch 
effects. tSNE plots show cells from replicate 1 (left) and replicate 2 (right) coloured by 
condition and genotype (PBS-treated wild-type mice (light grey), HDM-treated wild-type 
mice (red), PBS-treated Nmur1-knockout mice (dark grey), HDM-treated Nmur1-knockout 
mice (salmon)). c, d, Signature-based scoring of ILCs. Density plots show the distribution of 
scores for ILC1, 2 and 3 signatures in the cells from indicated treatment conditions. Dashed 
line indicates the cut-off for each signature used in assigning ILC type. e, Composition by 
ILC type. Bar plot shows proportion of each ILC type in the conditions indicated. f, ILC 
proliferation is strongly increased by IL-25 combined with NMU. Violin plots show the 
distribution of proliferation scores (y axis) across the cells in indicated conditions (x axis) 
(white diamond, mean; lines, first and third quartiles). g, Similar clusters are induced by 
HDM and by IL-25 combined with NMU treatment. tSNE plot shows ILCs from PBS- and 
HDM-treated wild-type and Nmur1-knockout mice (as in Fig. 5a), coloured by cluster and 
labelled by post hoc annotations. Note similarity to clustering in Fig. 4b. h, Cluster-specific 
ILC proliferation in cells from HDM-treated mice. Violin plots show the distribution of 
proliferation scores (y axis) across the cells in each cluster (x axis), as in g.
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Figure 1. IL-25 and IL-33 induce multiple distinct transcriptional programs in ILCs
ILCs were profiled by droplet-based scRNA-seq. a, b, t-Distributed stochastic neighbour 
embedding (tSNE) plots show 24,187 cells (dots) in a nonlinear representation of the top 22 
principal components (PCs). Cells are coloured by in vivo treatment (a) or cluster (b). c, d, 
Clustering reflects ILC type and treatment. Proportions of ILC subsets (c) or treatment 
condition (d) within each cluster. e, Distribution of proliferation scores by cluster. Diamond 
indicates the mean; lines, first and third quartiles. f, Representative differentially expressed 
genes (x axis) by cluster (y axis). Dot size represents the fraction of cells in the cluster that 
express the gene; colour indicates the mean expression (logTPX (see Methods)) in 
expressing cells, relative to other clusters.
Wallrapp et al. Page 34
Nature. Author manuscript; available in PMC 2017 December 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. ScRNA-seq identifies Nmur1 as a novel ILC2-specific gene
a–c, Full-length scRNA-seq. a, b, tSNE plots of 606 cells coloured by in vivo treatment (a) 
and cell clusters (b). c, Differentially expressed genes by cluster. Nmur1 is indicated in bold. 
d, Nmur1 expression by qPCR of lung-resident cell types isolated from control or HDM-
challenged mice. Data points are technical replicates (PBS, n = 3; HDM, n = 2). e, 
Representative flow cytometry histograms of NMUR1 expression on the indicated cell types. 
f, Frequency of NMUR1+ ILCs determined by flow cytometry after the indicated treatments. 
Data points are individual mice (PBS and IL-33, n = 4; IL-25, n = 3). Data in panels d, f are 
representative of two individual experiments. Mean is indicated. Error bars, s.e.m.; *P < 0.05 
(one-way ANOVA).
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Figure 3. NMU amplifies IL-25-induced allergic inflammation
a, b, IL-5 and IL-13 levels in cultured ILCs. a, RNA levels determined by qPCR. b, Protein 
concentration determined by LegendPlex (see Methods). One of three independent 
experiments is shown. Data points are technical replicates (n = 2). c, BALF IL-5 and IL-13 
concentrations determined by LegendPlex. d, BAL eosinophil frequency and number after 
treatment. e, Lung histology. Representative images (left) and severity score (right). Data 
points in c–e represent individual mice (PBS, n = 3; IL-25, n = 9; IL-25 combined with 
NMU, n = 7). f, Airway resistance (Rrs) after graded methacholine (MeCh) challenge. Data 
points represent the mean of biological replicates (IL-25, n = 7; IL-25 combined with NMU, 
n = 6). g, h, ILC responses after HDM challenge. g, Frequency of ST2+ ILCs by flow 
cytometry. Data points are individual mice (wild-type (WT), n = 15; knockout (Nmu KO), n 
= 13). h, Frequency of ILCs expressing IL-5 or IL-13, by intracellular cytokine staining. 
Data points are individual mice (n = 5) in one of three individual experiments. Mean is 
indicated. Error bars, s.e.m.; *P < 0.05 by two-tailed t-test (a, b, e, g, h), one-way ANOVA 
(c, d), or two-way ANOVA (f); NS, not significant.
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Figure 4. IL-25 and NMU synergize to activate inflammatory ILC2s
a, b, IL-25 combined with NMU induces distinct transcriptional states. tSNE plots of 35,542 
ILCs from mice treated with the indicated stimuli, coloured by treatment (a) and cluster (b). 
c, ILC frequency determined by flow cytometry. d, Distribution of proliferation scores by 
treatment condition. Diamond indicates the mean; lines, first and third quartiles. e–g, IL-25 
combined with NMU enhances IL-17RB expression on ILCs. e, IL-17RB+ ILC frequency by 
flow cytometry in one of two independent experiments. f, Frequency of Il17rb-expressing 
ILCs determined by scRNA-seq; *P < 2.73 × 10−10, logistic regression. g, IL-17RB+ ILC 
frequency after HDM challenge as determined by flow cytometry. h, Differentially 
expressed genes (y axis) by condition (x axis). Data points in c, e, g are individual mice (in 
c: PBS, n = 3; IL-25, n = 9; IL-25 combined with NMU, n = 7; in e: IL-25, n = 8; IL-25 
combined with NMU, n = 6; in g: wild-type, n = 5; Nmu-knockout, n = 5). Mean is 
indicated. Error bars, s.e.m.; *P < 0.05 by one-way ANOVA (c) or two-tailed t-test (d, e, g).
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Figure 5. NMUR1-signalling regulates ILC responses after allergen challenge
a, HDM challenge induces distinct transcriptional states. ScRNA-seq profiles of 21,895 
ILCs from wild-type (WT; left) and Nmur1-knockout (KO; right) on the same tSNE plot, 
coloured by treatment and genotype. b, Proportions of ILC subsets in each condition and 
genotype. c–e, An inflammatory ILC2 gene signature based on differential expression 
between ILCs from PBS- and HDM-treated mice. c, d, ILCs coloured by inflammatory 
ILC2 score, from HDM-challenged mice (c) and mice treated with PBS, NMU, IL-25 or 
IL-25 combined with NMU (d). e, Distribution of inflammatory ILC2 scores (y axis) in the 
indicated conditions. Diamond indicates the mean; lines, first and third quartiles; *P < 4.9 × 
10−15, two-tailed t-test.
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